AstraZeneca Annual Report and 144 Form 20-F Information 2005 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 7 SHARE CAPITAL Allotted, called-up Authorised and fully paid 2005 2005 2004 $m $m $m Issued Ordinary Shares $0.25 each 395 395 411 Unissued Ordinary Shares $0.25 each 205 Redeemable Preference Shares 1 each 50,000 600 395 411 The Redeemable Preference Shares carry limited class voting rights and no dividend rights.
This class of shares is capable of redemption at par at the option of the Company on the giving of seven days written notice to the registered holder of the shares.
The movements in share capital during the year can be summarised as follows: No.
of shares million $m At beginning of year 1,645 411 Issues of shares 41 Re-purchase of shares 68 17 At 31 December 2005 1,581 395 Share re-purchases During the year the Company re-purchased, and subsequently cancelled, 67,650,000 Ordinary Shares at an average price of 2445 pence per share.
The total consideration, including expenses, was $3,001m.
The excess of the consideration over the nominal value has been charged against the profit and loss account reserve.
Share schemes A total of 3,500,109 Ordinary Shares were issued during the year in respect of share schemes.
Details of movements in the number of Ordinary Shares under option are shown in Note 24: details of options granted to Directors are shown in the Directors Remuneration Report.
Shares held by subsidiaries No shares in the Company are held by subsidiaries.
8 STATUTORY AND OTHER INFORMATION There are no employees of the Company 2004 nil.
The directors of the Company were paid by another Group company in 2005 and 2004.
The fee for the audit of the Company is $1,600 2004 $1,600.
The Company has guaranteed the external borrowing of a subsidiary, in the amount of $285m.
Group Financial Record 145 GROUP FINANCIAL RECORD IFRS 2003 2004 2005 For the year ended 31 December $m $m $m Turnover and profits Sales 18,849 21,426 23,950 Cost of sales 4,463 5,193 5,356 Distribution costs 162 177 211 Research and development 3,012 3,467 3,379 Selling, general and administrative costs 7,393 8,268 8,695 Other operating income 188 226 193 Operating profit 4,007 4,547 6,502 Profit on sale of interest in joint venture 219 Finance income 381 532 665 Finance expense 311 454 500 Profit before tax 4,077 4,844 6,667 Taxation 1,033 1,161 1,943 Profit for the period 3,044 3,683 4,724 Attributable to: Equity holders of the Company 3,022 3,664 4,706 Minority interests 22 19 18 Earnings per share Earnings per $0.25 Ordinary Share before exceptional items $1.77 $2.01 $2.91 Earnings per $0.25 Ordinary Share basic $1.77 $2.18 $2.91 Earnings per $0.25 Ordinary Share diluted $1.77 $2.18 $2.91 Dividends $0.725 $0.835 $1.025 Return on sales Operating profit as a percentage of sales 21.3% 21.2% 27.2% Ratio of earnings to fixed charges IFRS 100.4 93.6 85.6 2003 2004 2005 At 31 December $m $m $m Balance sheet Property, plant and equipment and intangible assets 10,574 11,147 9,697 Other investments 133 262 256 Deferred tax assets 1,261 1,218 1,117 Current assets 11,593 13,025 13,770 Total assets 23,561 25,652 24,840 Current liabilities 6,558 6,587 6,839 Non-current liabilities 3,828 4,568 4,310 Net assets 13,175 14,497 13,691 Capital and reserves attributable to equity holders 13,086 14,404 13,597 Minority equity interests 89 93 94 Total equity and reserves 13,175 14,497 13,691 2003 2004 2005 For the year ended 31 December $m $m $m Cash flows Net cash inflow outflow from: Operating activities 3,368 4,817 6,743 Investing activities 852 970 1,182 Financing activities 2,674 2,761 4,572 158 3,026 989
